Reboxetine Mesylate is an organic compound with the chemical formula C20H27NO6S, which is mainly used in the treatment of disorders such as depression and anxiety.The structure of Reboxetine Mesylate contains a methanesulfonic acid group (-SO₃H) and a Reboxetine portion.Reboxetine is a pharmaceutically specific molecule and the inclusion of the methanesulfonic acid moiety may help to improve the pharmacological properties of the drug such as solubility, stability and bioavailability. The primary use of Reboxetine Mesylate is in the treatment of depression in adults. It improves the mood of patients by increasing the activity of NE within the centre by inhibiting the reuptake of norepinephrine (NE).
 |
 |
The main pharmacological effects of Reboxetine Mesylate include:
Inhibition of 5-hydroxytryptamine reuptake
Reboxetine Mesylate selectively binds to the 5-hydroxytryptamine transporter on the presynaptic membrane and blocks the release of 5-hydroxytryptamine from the neuron. This blockade prolongs the concentration of 5-hydroxytryptamine in the synaptic gap, thereby increasing the effect of 5-hydroxytryptamine on postsynaptic receptors and exerting an antidepressant effect.
Enhancement of Norepinephrine and Dopamine
Reboxetine Mesylate also has the ability to enhance the effects of norepinephrine and dopamine. Both of these neurotransmitters are involved in the process of mood regulation and emotional expression and also play an important role in the onset and development of depression. Therefore, Reboxetine Mesylate may improve patients' mood states by enhancing the effects of these neurotransmitters.
Specifically, the benefits and effects of Reboxetine Mesylate are as follows:
Treatment of depression
Reboxetine Mesylate is a commonly used antidepressant drug, which mainly increases the concentration of the neurotransmitter 5-hydroxytryptamine by inhibiting its reuptake and exerts sedative and antidepressant effects. For patients with mild to severe depression, taking this medication can help relieve symptoms and promote recovery.
Treatment of Anxiety Disorders
Reboxetine Mesylate is effective in reducing tension and restlessness in patients with anxiety disorders, helping them regain normal social skills and quality of life.
In addition, Reboxetine Mesylate can also be used to treat other disorders such as obsessive-compulsive disorder.
Domestic R&D Trends
As an important part of the new productivity, the biomedical industry was mentioned in this year's work report, in which the "innovative drug" industry was written into the work report for the first time. In this context, the company plans to be based on the "four directions" (science and technology innovation should be oriented to the world's scientific and technological frontiers, to the main battlefield of the economy, to the major needs of the country, and to the people's lives and health), aiming to jointly build a high-level national innovation platform, and to become an important participant in the global biopharmaceuticals and the rule-setters.
According to the introduction, joint research and systematic layout will be carried out in the future in five directions, including new drug discovery and translation, novel vaccines, drug product science and advanced formulation, pharmaceutical cross-engineering, and policy and strategy. It will also take on the important task of cultivating leading talents in the field of medicine with academic activeness, international vision and development potential.
Leading the high-quality development of the enterprise through scientific and technological innovation is the top priority of our current work, and also the direct motive for the continuous development of cooperation. The company attaches importance to the mechanism of stable growth of R&D investment, with a cumulative R&D investment of 26.5 billion yuan from 2020-2023, an average annual growth rate of R&D investment of more than 30%, and an average intensity of industrial R&D investment of 7.9%, the sustained growth of scientific and technological investment powerfully guarantees the smooth progress of nearly 1,000 R&D projects.
High-level research universities and science and technology leading enterprises are both important parts of the country's strategic scientific and technological forces. At present, in university-enterprise co-operation, it is difficult to match smoothly between the potential innovation capacity of universities and the key technological needs of enterprises. Therefore, there is an urgent need for enterprises and universities to take a "key step" forward. Enterprises should take the initiative to transform the core technological challenges they face into scientific problems that can be understood and agreed upon by university researchers, while universities should actively go into the production and research frontline of enterprises to identify and refine key technological problems.
Our Philosophy
Adhering to the corporate philosophy of "blessing life and caring for health", the company vigorously implements the innovation-driven development strategy, strengthens the status of enterprise innovation main body, creates an innovation system that deeply integrates industry, academia and research, actively serves the national strategy, and protects the people's health. For the first time, the Group has established a joint research institute with a top university in China, creating a new paradigm of deep integration of industry, academia and research. The establishment of the Joint Research Institute is an important strategic initiative of the decision-making deployment, aiming to build a high-level national innovation platform based on the "four directions", and to become an important participant and rule maker in global biopharmaceuticals.
Future expectations
The leaders put forward four hopes for the future development: first, we should have a "country's greatness" in mind, and enhance the insight into the major national needs; second, we should strengthen the forward-looking thinking and systematic layout, and condense the key scientific issues and promote the primitive innovation; third, we should focus on the long term, lay a solid foundation, and do the truly valuable scientific research; fourth, we should maintain an open posture, and strengthen the international scientific and technological cooperation and exchange. Fourthly, we should maintain an open attitude and strengthen international scientific and technological exchanges and cooperation.
In his speech, he said that he would actively provide strong support for the development of the work of the Joint Research Institute and the clinical transformation of scientific research results, and hoped that the Joint Research Institute would become a landmark and exemplary model of collaborative innovation between industry, academia and research, benefiting the general public with real innovation results, and contributing to the implementation of the strategy of Healthy China.
The company has conducted exchanges and discussions on topics such as further promoting the complementary advantages of university and enterprise resources, promoting the cross-discipline and results transformation, and actively exploring new paradigms of cooperation. The company will continue to promote exchanges and cooperation in scientific research, talent and technology transformation in the field of biomedicine.